FDA to modernise review process for developers of ultra-rare diseases

The US Food and Drug Administration (FDA) is proposing a new procedure for rare disease clinical trials to help expedite their review.

The Rare Disease Evidence Principles (RDEP) process is intended to assure trial sponsors that the FDA’s assessments will encompass additional supportive data.